Paras H. Shah, MD, recaps data on emerging agents in high-risk NMIBC from the 2026 AUA North Central Section Meeting.
|Videos|October 11, 2021
Dr. Matulewicz on smoking status data in genitourinary cancer trials
Author(s)Urology Times staff
Advertisement
In this video, Richard Matulewicz, MD, MS, discusses the background and findings of the study, “Persistent deficiencies in the measurement and reporting of tobacco use in contemporary genitourinary oncology clinical trials,” presented recently at the 2021 American Urological Association Annual Meeting. Matulewicz is an assistant professor in the department of urology at Memorial Sloan Kettering Cancer Center, New York City.
Advertisement
Related to this article
Andrea Necchi, MD, discusses how results from the CA017-078 trials compares with other perioperative immunotherapy trials in muscle-invasive bladder cancer.
Michael S. Cookson, MD, MMHC, FACS, discusses how Anktiva’s expanded FDA approval may broaden bladder-preserving treatment options for BCG-unresponsive papillary-only NMIBC.
Alicia Morgans, MD, discusses ARACOG findings on cognitive outcomes with darolutamide vs enzalutamide and the influence of genetic dementia risk.
The phase 1 study is intended to characterize the safety, tolerability, and feasibility of intravesical administration of UGN-501.
Elie Kaplan-Marans, MD, discusses geographic disparities in reproductive urology access and how work force gaps may affect comprehensive infertility evaluations.
Aaron Berger, MD, discusses patient selection for ARPI treatment holidays, monitoring during interruptions, and the role of testosterone recovery in interpreting PSA kinetics.
Five-year follow-up data show durable responses with UGN-101 in patients with low-grade upper tract urothelial carcinoma who achieved an initial complete response.
Advertisement
Advertisement
Trending on Urology Times
1
UGN-501 enters phase 1 testing for recurrent non–muscle invasive bladder cancer
2
ESMO 2026 On Location - Why pCR is not the whole story in cisplatin-ineligible MIBC
3
2026 AUA North Central Section Meeting: Updates in high-risk NMIBC
4
UGN-101 shows durable responses in low-grade upper tract urothelial carcinoma
5